在心力衰竭中管理心房动:在谁,何时,以及如何?
Panteleimon E Papakonstantinou1, Gregory Y H Lip2,3,4
1Atrial Fibrillation Institute, Heart and Vascular Centre and Cardiovascular Research Institute Dublin, Royal College of Surgeons of Ireland, Mater Private Hospital, Dublin, Ireland.
International journal of heart failure
|February 16, 2026
概括
在心力衰竭 (HF) 患者中管理心房动 (AF) 是复杂的. 早期节律控制,特别是导管切除,显示在选定的HF患者中改善了生存率和减少了住院治疗.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 心脏衰竭管理的管理
背景情况:
- 心房动 (AF) 和心力衰竭 (HF) 经常同时存在,使彼此的进展和结果恶化.
- 在HF患者中管理AF需要对节律控制,速率控制和抗凝药进行复杂的决策.
研究的目的:
- 综合当前关于管理HF患者的AF的证据.
- 提供实用临床算法,用于高频AF中综合,以患者为中心的AF管理.
主要方法:
- 最近随机试验和更新的指导方针的叙述性审查.
- 分析了AF和HF之间的病理生理机制.
- 评估节律控制策略,包括导管切除.
主要成果:
- 早期节律控制,特别是导管切除,改善了生存率,并减少了选择的HF患者中HF住院治疗的减少喷射分数.
- 共享的病理生理机制包括神经激素激活,结构重塑和心房肌病.
- 直接口服抗凝剂对于降低血栓栓塞的风险至关重要.
结论:
- 导管切除是一种首选的节律控制策略,用于减少射出分数的HF.
- AF干预的最佳时间和方法取决于患者特定的因素.
- 综合,多学科和以患者为中心的护理对于管理高频AF至关重要.
相关概念视频
Heart Failure VI: Adjunct Therapies
403
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
403
Heart Failure V: Medical Management
369
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
369
Dysrhythmias VI: Management of Dysrhythmias
498
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
498
Heart Failure Drugs: β-Blockers
984
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
984
Heart Failure IV: Classification and Diagnostic Evaluation
441
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
441
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K


